3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Prostatic Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Stomach Neoplasms
2
Oropharyngeal Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
Retinoblastoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Osteoporosis
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Interventions
Cisplatin
130
Cetuximab
79
Radiotherapy
76
Docetaxel
58
Carboplatin
46
pembrolizumab
45
Paclitaxel
44
Fluorouracil
42
Radiotherapy, Intensity-Modulated
35
Drug Therapy
17
Radiation
14
Nivolumab
14
Gefitinib
14
Gemcitabine
13
Surgical Procedures, Operative
12
Oxaliplatin
11
Erlotinib Hydrochloride
11
Pemetrexed
10
Celecoxib
10
Capecitabine
10
Bevacizumab
10
130-nm albumin-bound paclitaxel
10
tislelizumab
9
Filgrastim
9
Amifostine
9
Albumin-Bound Paclitaxel
9
durvalumab
7
atezolizumab
7
Chemoradiotherapy
7
toripalimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Head and Neck Neoplasms
×
Observation
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled